Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare progression-free survival (PFS) in subjects with pancreatic islet cell tumors treated with sunitinib (at a starting dose of 37.5 mg daily continuous dosing) with those treated with placebo
Critère d'inclusion
- Progressive, advanced/metastatic well-differentiated pancreatic islet cell tumours